RS51818B - Supstituisani karboksamidi kao antagonisti grupe i metabotrofičnih receptora - Google Patents

Supstituisani karboksamidi kao antagonisti grupe i metabotrofičnih receptora

Info

Publication number
RS51818B
RS51818B RS20110336A RSP20110336A RS51818B RS 51818 B RS51818 B RS 51818B RS 20110336 A RS20110336 A RS 20110336A RS P20110336 A RSP20110336 A RS P20110336A RS 51818 B RS51818 B RS 51818B
Authority
RS
Serbia
Prior art keywords
formula
compound
mmol
phenyl
pain
Prior art date
Application number
RS20110336A
Other languages
English (en)
Serbian (sr)
Inventor
Matthew Joseph Fisher
Sean Patrick Hollinshead
Ryan Thomas Backer
Steven Lee Kuklish
Edward C.R. Smith
Kumiko Takeuchi
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of RS51818B publication Critical patent/RS51818B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20110336A 2006-06-08 2007-06-07 Supstituisani karboksamidi kao antagonisti grupe i metabotrofičnih receptora RS51818B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81183906P 2006-06-08 2006-06-08

Publications (1)

Publication Number Publication Date
RS51818B true RS51818B (sr) 2011-12-31

Family

ID=39673278

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20110336A RS51818B (sr) 2006-06-08 2007-06-07 Supstituisani karboksamidi kao antagonisti grupe i metabotrofičnih receptora

Country Status (30)

Country Link
US (1) US7960419B2 (enExample)
EP (1) EP2076502B1 (enExample)
JP (1) JP5108878B2 (enExample)
KR (1) KR101051559B1 (enExample)
CN (1) CN101466691B (enExample)
AT (1) ATE509921T1 (enExample)
AU (1) AU2007347428B2 (enExample)
BR (1) BRPI0712862A2 (enExample)
CA (1) CA2652074C (enExample)
CR (1) CR10410A (enExample)
CY (1) CY1111588T1 (enExample)
DK (1) DK2076502T3 (enExample)
EA (1) EA014233B1 (enExample)
EC (1) ECSP088939A (enExample)
ES (1) ES2362949T3 (enExample)
HR (1) HRP20110436T1 (enExample)
IL (1) IL195632A (enExample)
MA (1) MA30620B1 (enExample)
MX (1) MX2008015485A (enExample)
MY (1) MY148084A (enExample)
NO (1) NO341474B1 (enExample)
NZ (1) NZ573352A (enExample)
PL (1) PL2076502T3 (enExample)
PT (1) PT2076502E (enExample)
RS (1) RS51818B (enExample)
SI (1) SI2076502T1 (enExample)
TN (1) TNSN08506A1 (enExample)
UA (1) UA95480C2 (enExample)
WO (1) WO2008103185A2 (enExample)
ZA (1) ZA200809111B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0804685D0 (en) 2008-03-13 2008-04-16 Univ Edinburgh Therapeutic compounds and their use
MX2010010781A (es) 2008-04-04 2010-12-14 Lilly Co Eli 3-indazolil-4-piridilisotiazoles.
EP2443113A1 (en) * 2009-06-15 2012-04-25 The University Of Edinburgh Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders
JP5779181B2 (ja) 2009-09-16 2015-09-16 ザ ユニバーシティ オブ エディンバラ （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
EP2563780B1 (en) 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
DK2921489T3 (en) 2012-11-13 2017-10-16 Nissan Chemical Ind Ltd 2-pyridone-RELATED
AU2017329677A1 (en) 2016-09-23 2019-04-18 Bayer Aktiengesellschaft N 3 -cyclically substituted thienouraciles and use thereof
CN117567266B (zh) * 2023-11-07 2024-06-14 康龙化成手性医药技术(宁波)有限公司 一种制备2-甲基环丙羧酸的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72091A0 (en) 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-aryl 5-isothiazolyl)urea derivatives
DE4328425A1 (de) 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
DK124393D0 (da) 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
DE19542372A1 (de) * 1995-11-14 1997-05-15 Bayer Ag Acylierte 5-Aminoisothiazole
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP3411262B2 (ja) * 1999-08-20 2003-05-26 萬有製薬株式会社 新規スピロ化合物
JP2005501073A (ja) * 2001-08-06 2005-01-13 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬活性を有するアミノイソオキサゾール誘導体
EP1667983A4 (en) * 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
WO2005113534A2 (en) * 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
BRPI0515571A (pt) * 2004-09-23 2008-07-29 Pfizer Prod Inc agonistas de receptor de trombopoetina

Also Published As

Publication number Publication date
EP2076502A2 (en) 2009-07-08
JP2009539874A (ja) 2009-11-19
MY148084A (en) 2013-02-28
CA2652074A1 (en) 2008-08-28
MX2008015485A (es) 2009-03-06
EA014233B1 (ru) 2010-10-29
PT2076502E (pt) 2011-06-07
SI2076502T1 (sl) 2011-09-30
DK2076502T3 (da) 2011-07-25
KR101051559B1 (ko) 2011-07-22
ECSP088939A (es) 2009-01-30
IL195632A0 (en) 2009-09-01
TNSN08506A1 (en) 2010-04-14
HRP20110436T1 (hr) 2011-08-31
CR10410A (es) 2008-11-28
US20090182025A1 (en) 2009-07-16
EA200870516A1 (ru) 2009-06-30
NO341474B1 (no) 2017-11-27
AU2007347428A1 (en) 2008-08-28
CN101466691A (zh) 2009-06-24
EP2076502B1 (en) 2011-05-18
JP5108878B2 (ja) 2012-12-26
ES2362949T3 (es) 2011-07-15
WO2008103185A2 (en) 2008-08-28
PL2076502T3 (pl) 2011-09-30
WO2008103185A3 (en) 2008-10-30
ATE509921T1 (de) 2011-06-15
ZA200809111B (en) 2009-12-30
CY1111588T1 (el) 2015-10-07
NO20085028L (no) 2008-12-02
IL195632A (en) 2013-11-28
AU2007347428B2 (en) 2012-02-09
CN101466691B (zh) 2011-07-27
HK1131984A1 (en) 2010-02-12
CA2652074C (en) 2013-08-06
BRPI0712862A2 (pt) 2012-12-18
KR20090008460A (ko) 2009-01-21
US7960419B2 (en) 2011-06-14
UA95480C2 (uk) 2011-08-10
NZ573352A (en) 2011-10-28
MA30620B1 (fr) 2009-08-03

Similar Documents

Publication Publication Date Title
RS51818B (sr) Supstituisani karboksamidi kao antagonisti grupe i metabotrofičnih receptora
JP4054368B2 (ja) 置換メチルアリール又はヘテロアリールアミド化合物
RU2140414C1 (ru) Производные изоксазола, их применение в производстве ингибирующего моноаминооксидазу агента, фармацевтическая композиция и способ ингибирования моноаминооксидазы типа в
CN105120860B (zh) 组蛋白脱乙酰酶抑制剂
KR101198057B1 (ko) 신규한 ｎ-(2-아미노-페닐)-아미드 유도체
WO2010118354A1 (en) Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof
JP2025081557A (ja) （２，５－ジオキソピロリジン－１－イル）（フェニル）－アセトアミド誘導体、および神経疾患の処置におけるその使用
CN101309909B (zh) 作为钙和/或钠通道调节剂的2-苯基乙基氨基衍生物
Więckowski et al. Search for anticonvulsant and analgesic active derivatives of dihydrofuran-2 (3H)-one
AU2012384456B2 (en) Novel cholecystokinin receptor ligands
AU2015308438B2 (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
CN117820236A (zh) 组蛋白乙酰转移酶小分子抑制剂及其制备方法和用途
HK1131984B (en) Substituted carboxamides as group i metabotropic receptor antagonists
RS51555B (sr) O-supstituisani-dibenzil urea-derivati kao antagonisti trpv1 receptora
CN106810532B (zh) 一类胺烷氧基噻吨酮类化合物、其制备方法和用途
WO2018163077A1 (en) Indanyl compounds as voltage gated sodium channel modulators
Di Fabio et al. Synthesis and pharmacological characterisation of a conformationally restrained series of indole-2-carboxylates as in vivo potent glycine antagonists
EP4417601A1 (en) Small molecule treatment of fatty liver disease and hcc
CN116925066A (zh) 吲哚噻唑酮类化合物及其应用
Sheorey et al. PHARMACOLOGICAL EVALUATION OF 3-ETHYL-2-SUBSTITUTEDAMINO-3H-QUINAZOLIN-4-ONES AS ANALGESIC AND ANTI-INFLAMMATORY AGENTS